Home Featured Page 257

Featured

Latest

Senate Bill S.4031 Signals a Federal Turn Toward Psychedelic Medicine

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine, and Scientific Rigour

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

The Psilocybin vs. Escitalopram Trial – Part 2

Psychedelics and Cannabis ETF Launches on NYSE Arca in First for...

Cybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure...

PharmaTher and TSRL Enter into Co-Development Agreement For Microneedle Patch Delivery...

Small Pharma Inc. Expands Phase I/IIa Clinical Trial With Additional Study...

PT246 – Amber and Marcus Capone of VETS – Foundational Healing...

MYND Life Sciences announces Depression Biomarker Diagnostic Program

Horizons ETFs Announces Methodology Update for the North American Psychedelics Index

Filament Health Partners with TrPR Psychedelic Research Program at UCSF to...

Can Psychedelics Help Heal Moral Injury?

EDITOR PICKS

Senate Bill S.4031 Signals a Federal Turn Toward Psychedelic Medicine

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Senate Bill S.4031 Signals a Federal Turn Toward Psychedelic Medicine

Psychedelic Culture 2026

TRYP EXPO

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine, and Scientific Rigour

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

The Psilocybin vs. Escitalopram Trial – Part 2

Psychedelics and Cannabis ETF Launches on NYSE Arca in First for...

Cybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure...

PharmaTher and TSRL Enter into Co-Development Agreement For Microneedle Patch Delivery...

Small Pharma Inc. Expands Phase I/IIa Clinical Trial With Additional Study...

PT246 – Amber and Marcus Capone of VETS – Foundational Healing...

MYND Life Sciences announces Depression Biomarker Diagnostic Program

Horizons ETFs Announces Methodology Update for the North American Psychedelics Index

Filament Health Partners with TrPR Psychedelic Research Program at UCSF to...

Can Psychedelics Help Heal Moral Injury?

EDITOR PICKS

Senate Bill S.4031 Signals a Federal Turn Toward Psychedelic Medicine

Psychedelic Culture 2026

TRYP EXPO

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY